April 27, 2006 08:00 ET

Ceapro receives prestigious international award

EDMONTON, April 27 - Ceapro Inc. (TSX VENTURE:CZO) today announced that
Frost & Sullivan have awarded Ceapro the 2006 Product Innovation Award in
recognition of CeaProve® the pioneering point-of-care diagnostic product for
type 2 diabetes and pre-diabetes.

"It is a great honour to receive such a prestigious international award,"
said Dr. Mark Redmond, Ceapro's President and CEO. "The recognition will help
establish a global profile for Ceapro and focus attention on our CeaProve®
technology. We are confident that CeaProve® is poised to make a significant
contribution to international health and addressing the global diabetes

The Frost & Sullivan Award for Product Innovation is presented each year
to the company that has demonstrated excellence in new products and
technologies within their industry. The recipient company has shown innovation
by launching a broad line of emerging products and technologies. The
measurement criteria for the award include:

- Significance of new product
- Competitive advantage of new product
- Product innovation in terms of unique or revolutionary technology
- Product acceptance in the marketplace
- New product value-added services provided to customers
- Number of competitors with similar product

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more than
40 years. The company's industry expertise integrates growth consulting,
growth partnership services and corporate management training to identify and
develop opportunities. Frost & Sullivan serves an extensive clientele that
includes Global 1000 companies, emerging companies, and the investment
community, by providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets, technologies,
econometrics, and demographics. For more information, visit www.frost.com.

About CeaProve®

CeaProve® is a simple, cost effective, and rapid point-of-care tool to
detect the elevated blood glucose levels indicative of pre-diabetic and
diabetic conditions. CeaProve® consists of calibrated wafers made from a
proprietary formulation of proteins, fats, and complex carbohydrates that are
consumed with a glass of water after an overnight fast. A quick analysis of
the blood, using one of many standard glucose meters presently on the market,
provides an on-the-spot indication of elevated blood glucose levels.

About Ceapro Inc.

Ceapro Inc is a growth stage biotechnology company. Ceapro's core
technology is the extraction of functional, active ingredients. We will
continue to add value to our extracts by manufacturing medical and therapeutic
products, support the use of our extracts in products for human and animal
health and introduce health and wellness services employing our CeaProve®
diagnostic technology. Ceapro shares trade on the TSX Venture Exchange under
the symbol CZO. To learn more about Ceapro, visit our website at
www.ceapro.com. Shares Outstanding: 37,098,670, Recent Close: $0.265.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary

Contact Information

  • Dr. Mark Redmond, President & CEO, Ceapro Inc.,
    Telephone: (780) 421-4555